Zacks: Brokerages Expect Vanda Pharmaceuticals Inc. (VNDA) Will Announce Quarterly Sales of $44.00 Million

Wall Street brokerages expect that Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) will report sales of $44.00 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Vanda Pharmaceuticals’ earnings. Vanda Pharmaceuticals posted sales of $38.24 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 15.1%. The firm is scheduled to report its next quarterly earnings results on Wednesday, February 21st.

According to Zacks, analysts expect that Vanda Pharmaceuticals will report full year sales of $44.00 million for the current year, with estimates ranging from $164.80 million to $170.10 million. For the next year, analysts forecast that the firm will report sales of $204.50 million per share, with estimates ranging from $193.00 million to $214.70 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Vanda Pharmaceuticals.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). The company had revenue of $41.30 million during the quarter, compared to analysts’ expectations of $43.90 million. Vanda Pharmaceuticals had a negative net margin of 9.01% and a negative return on equity of 10.99%. The firm’s quarterly revenue was up 7.3% on a year-over-year basis. During the same period in the previous year, the company earned ($0.01) EPS.

Several equities research analysts have issued reports on the stock. Oppenheimer Holdings, Inc. reissued a “buy” rating and issued a $25.00 price objective on shares of Vanda Pharmaceuticals in a research report on Sunday, November 12th. BidaskClub cut shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. HC Wainwright set a $18.00 price objective on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 3rd. ValuEngine cut shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. Finally, Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a research report on Wednesday, October 18th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $21.50.

Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) opened at $12.95 on Friday. Vanda Pharmaceuticals has a 52-week low of $11.90 and a 52-week high of $18.99.

Large investors have recently bought and sold shares of the company. Legal & General Group Plc raised its holdings in shares of Vanda Pharmaceuticals by 37.4% in the 2nd quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock valued at $181,000 after purchasing an additional 3,022 shares in the last quarter. Kopp Investment Advisors LLC bought a new stake in shares of Vanda Pharmaceuticals in the 2nd quarter valued at about $196,000. Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of Vanda Pharmaceuticals in the 3rd quarter valued at about $277,000. American International Group Inc. raised its holdings in shares of Vanda Pharmaceuticals by 7.1% in the 1st quarter. American International Group Inc. now owns 22,563 shares of the biopharmaceutical company’s stock valued at $316,000 after purchasing an additional 1,491 shares in the last quarter. Finally, Voya Investment Management LLC raised its holdings in shares of Vanda Pharmaceuticals by 29.7% in the 2nd quarter. Voya Investment Management LLC now owns 20,118 shares of the biopharmaceutical company’s stock valued at $328,000 after purchasing an additional 4,605 shares in the last quarter. Institutional investors and hedge funds own 87.28% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Zacks: Brokerages Expect Vanda Pharmaceuticals Inc. (VNDA) Will Announce Quarterly Sales of $44.00 Million” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://sportsperspectives.com/2017/11/19/zacks-brokerages-expect-vanda-pharmaceuticals-inc-vnda-will-announce-quarterly-sales-of-44-00-million.html.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply